Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.
Abstract
The proper dose and schedule of sunitinib have yet to be established for patients with metastatic renal cell carcinoma (RCC) on hemodialysis. We reviewed two patients with metastatic RCC on hemodialysis who had been treated with sunitinib in Yonsei Cancer Center, Yonsei University College of Medicine. Fifty milligrams of sunitinib was administered intermittently after each hemodialysis session (3 or 4 times a week). Overall responses were partial response in both cases. Progression-free survivals were 16 and 6 months, respectively, at the time of reporting (April 2010). Both subjects tolerated the treatment.
참고문헌 (12)
- Keith DS, "Renal cell carcinoma in autosomal dominant polycystic kidney disease", J Am Soc Nephrol, 4, pp.1661~1669 (1994)
- Hughson MD, "Renal neoplasia and acquired cystic kidney disease in patients receiving long-term dialysis", Arch Pathol Lab Med, 110, pp.592~601 (1986)
- Peces R, "Renal cell carcinoma co-existent with other renal disease: clinico-pathological features in predialysis patients and those receiving dialysis or renal transplantation", Nephrol Dial Transplant, 19, pp.2789~2796 (2004)
- Janus N, "Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients", Ann Oncol, 21, pp.1395~1403 (2010)
- Escudier B, "Sorafenib in kidney cancer", Ann Oncol, 18, pp.90~93 (2007)
- Escudier B, "Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial", Lancet, 370, pp.2103~2111 (2007)
- Motzer RJ, "Phase I", II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma, 2007, pp.25, 3958~3964
- Motzer RJ, "Sunitinib efficacy against advanced renal cell carcinoma", J Urol, 178, pp.1883~1887 (2007)
- Faivre S, "Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer", J Clin Oncol, 24, pp.25~35 (2006)
- Zastrow S, "Treatment of metastatic renal cell cancer with sunitinib during chronic hemodialysis", Urology, 73, pp.868~870 (2009)
- Park CY, "Successful sunitinib treatment of metastatic renal cell carcinoma in a patient with end stage renal disease on hemodialysis", Anticancer Drugs, 20, pp.848~849 (2009)
- 홍민희, "Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea", Cancer Research and Treatment, 41(2), pp.67~72 (2009), 대한암학회